In This Section

SU2C Catalyst™ Research Grants: Bristol-Myers Squibb Supported Projects

Grant Amount $3,000,000 USD
Grant Term3 Years
Start of Grant Term01/01/2017
Application Deadline08/22/2016 12:00 PM (AST)
Decision Date12/1/2016 12:00:00 AM
Description

The SU2C Catalyst Research Grants: BMS Supported Projects takes a structured and prioritized approach to early-phase clinical studies or translational research in order to accelerate the time to get potential new treatment options to patients and bring together all the key players in a collaborative and strategic manner. The project must include nivolumab, ipilimumab, elotuzumab, and/or urelumab alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following disease areas of interest: lung cancer, head & neck cancers, metastatic melanoma, merkel cell carcinoma, metastatic/invasive bladder cancer, lymphoma (Hodgkin and Non-Hodgkin), multiple myeloma, and Acute myleiod leukemia (AML). If a product is proposed for use that is marketed or is under development by another company, SU2C will act as an honest broker to secure the necessary agreements. Multi-investigator, multi-institutional projects are required. The project must be designed to accelerate the application of therapeutic agents or methods to study in the clinic (i.e., lead to patient enrollment in a study within the timeframe of the grant) and deliver near-term benefit through investigation and data generation by a collaborative SU2C Catalyst BMS Team of expert investigators. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early phase, signal-finding clinical trials is encouraged. Clinical trials must be planned so that the final patient is enrolled by the end of the grant term.

Research Project Criteria

The SU2C Catalyst Research Grants: BMS Supported Projects takes a structured and prioritized approach to early-phase clinical studies or translational research in order to accelerate the time to get potential new treatment options to patients and bring together all the key players in a collaborative and strategic manner. The project must include nivolumab, ipilimumab, elotuzumab, and/or urelumab alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following disease areas of interest: lung cancer, head & neck cancers, metastatic melanoma, merkel cell carcinoma, metastatic/invasive bladder cancer, lymphoma (Hodgkin and Non-Hodgkin), multiple myeloma, and Acute myleiod leukemia (AML). If a product is proposed for use that is marketed or is under development by another company, SU2C will act as an honest broker to secure the necessary agreements. Multi-investigator, multi-institutional projects are required. The project must be designed to accelerate the application of therapeutic agents or methods to study in the clinic (i.e., lead to patient enrollment in a study within the timeframe of the grant) and deliver near-term benefit through investigation and data generation by a collaborative SU2C Catalyst BMS Team of expert investigators. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early phase, signal-finding clinical trials is encouraged. Clinical trials must be planned so that the final patient is enrolled by the end of the grant term.

Eligibility Criteria

Grant Amount: $1 Million - $3 Million
Expected Number of Funded Grants: Up to 4

The SU2C CatalystTM is a new collaborative initiative intended to leverage all stages of the pharmaceutical, biotechnology, diagnostic, and devices industries (collectively referred to herein as "industry") to bring new treatments to patients as rapidly as possible. SU2C is at the intersection between a large and highly skilled scientific community consisting of its Scientific Advisory Committee, Dream Teams, Translational Research Teams, and Innovative Research Grant recipients, academic institutions, and industry. The SU2C Catalyst establishes a mechanism through which industry and academic scientists in the cancer community will conduct SU2C collaborative research projects that will deliver significant benefits for patients and society, accelerating the development of new treatments and, where appropriate, combination therapies. As the Scientific Partner in the SU2C Catalyst, the American Association for Cancer Research (AACR) provides scientific oversight and conducts expert peer review and grants administration for SU2C.

The principles guiding SU2C collaborations with industry are designed to accelerate the pace of groundbreaking translational research that provides new therapies to patients rapidly:

  1. Integrity: Industry, academia, and SU2C will act with integrity at all times, putting patients at the center of everything we do.
  2. Independence: SU2C and affiliated researchers will maintain independent strategies, activities or information with unbiased scientific overview by its Executive Committee and associated Industry Steering Subcommittees.
  3. Transparency: SU2C will be transparent, consistent, and fair when collaborating with industry.
  4. Accountability: SU2C is accountable to many stakeholders and thus will not promote, endorse, or favor any particular product.

Citizenship Requirements

None

AACR Membership Requirements

None

Application Instructions

The AACR requires applicants to submit an online application. Completed online applications should be submitted by 12:00 p.m. (noon) United States Eastern Time on August 22, 2016. using the proposalCENTRAL website at https://proposalcentral.altum.com. An e-mail will be sent to confirm your online submission.